New Mechanism of FAD-Mediated FSP1 Stabilization Uncovered: Vitamin B2 Metabolism Emerges as a Novel Anticancer Target

In 2026, pivotal breakthroughs have been achieved in the research on ferroptosis regulatory mechanisms within the fields of tumor metabolism and biomedicine. A recent study published in Nature Structural & Molecular Biology reveals that flavin adenine dinucleotide (FAD), the active metabolite of vitamin B2 (riboflavin), acts as a core "molecular glue" to maintain FSP1 protein stability. This finding provides an innovative metabolic intervention strategy to overcome cancer drug resistance.

Through high-throughput genetic screening, the research team identified that FSP1, a key reductase inhibiting ferroptosis, is entirely dependent on FAD binding for its protein stability. In the absence of FAD, degradation signals of FSP1 become rapidly exposed. The protein is subsequently recognized and labeled by the E3 ubiquitin ligase RNF8, followed by degradation via the proteasome pathway. On the contrary, sufficient FAD stabilizes FSP1 structure, enabling it to exert potent antioxidant effects and allowing cancer cells to evade ferroptosis.

The elucidation of this mechanism redefines vitamin B2, elevating it from a mere nutrient to a critical metabolic switch governing cell fate. For the biomedical industry, it indicates that targeting the FAD synthesis pathway or disrupting the FSP1-FAD interaction can specifically dismantle the defense system of cancer cells. Currently, parallel studies are exploring the application of bacterial FAD analogs to impair FSP1 function, which broadens great prospects for the development of next-generation anticancer therapies.

FOR DETAIL：https://www.nature.com/articles/s41594-026-01760-4

Article from: